Ligand Pharmaceuticals Incorporated announced the appointment of Sarah Boyce to the Company's Board of Directors, effective October 15, 2019. Ms. Boyce currently serves as President and CEO of Avidity Biosciences Inc. Ms. Boyce's appointment increases the number of Ligand directors to nine. Prior to joining Avidity Biosciences in October 2019, Ms. Boyce served as a Director and President of Akcea Therapeutics. Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England.